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Abstract 
Objective: Recent findings suggest that β-adrenergic blockers have anti-nociceptive 
properties. The aim of this study was to compare levels of large joint pain between those on 
adrenergic blockers and those on other antihypertensive medications  
Methods: Data from the GOAL study, a secondary care cohort of osteoarthritis (OA), were 
used. Joint pain was assessed using the Western Ontario and McMaster Universities 
Arthritis (WOMAC) pain score in 873 individuals who had symptomatic hip and/or knee OA 
and hypertension, and who were on ≥1 prescription antihypertensive medications. The 
association between adrenergic blocker prescription and a) at least moderate joint pain 
(WOMAC <75), and b) use of prescription analgesics was examined using binary logistic 
regression. Analyses were adjusted for age, gender, BMI, knee or hip OA, history of joint 
replacement (at other joints), anxiety and depression.  
Results: Use of β-adrenergic blockers associated with lower WOMAC pain scores and with 
a lower prevalence of joint pain after adjustment for demographic variables and comorbidity 
(adjusted odds ratio (aORpain= 0.68 (95%C.I. 0.51-0.92; p<0.011)). No associations with pain 
were observed with use of α-blockers (aORpain= 0.94 (95%C.I. 0.55-1.58)) or with any other 
class of anti-hypertensive medications. Prescription of β-blockers also associated negatively 
with opioid use (aORopioids=0.73 (95%CI 0.54-0.98; p<0.037)) and with use of prescription 
analgesics in general (aORanalgesics=0.74 (95%CI 0.56-0.94; p<0.032)).  
Conclusion: Use of β-blockers associates with less joint pain and lower use of opioids and 
other analgesics in individuals with symptomatic large joint OA. This observation needs to be 
confirmed in other studies.  
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Key points: 
• Animal models and human studies suggest an anti-nociceptive role for beta 
adrenergic blockers.  
• We assessed, in individuals diagnosed with both osteoarthritis and 
hypertension, whether there were differences in the prevalence of joint pain 
and analgesic use among those on beta-blockers compared to other anti-
hypertensive medications.  
• We found that use of beta blockers is associated with a lower prevalence of 
joint pain and a lower use of prescription analgesics.  
• This finding raises the possibility that this class of drugs may be used as 
analgesics for joint pain. 
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Introduction 
Hypertension is a common comorbidity in older people and occurs in up to 40% of 
individuals with osteoarthritis (OA) [1]. Treatment of joint pain in hypertensive patients is a 
therapeutic challenge due to the adverse effects of some analgesics especially non-steroidal 
anti-inflammatory drugs (NSAIDs) on blood pressure [2]. The therapeutic focus to date has 
been on selecting analgesic medications that do not increase cardiovascular risk for these 
patients. Identification of anti-hypertensive medication that may reduce the need for 
analgesic drugs has not been investigated to date. 
Adrenergic neurotransmission is an integral part of the pathways that regulate the response 
to pain and stress [3]. The increase in α1-adrenoceptor expression after nerve and tissue 
injury plays a role in neuropathic pain syndromes [3] and β2-adrenergic receptor modulates 
the response to morphine via its heterodimerization with one of the splice forms of the mu 
opioid receptor 1 [4]. An anti-nociceptive effect of β-blockers has been demonstrated 
recently in a mouse model of chronic pain [5]. Importantly, both in patients with fibromyalgia 
and in those with temporomandibular joint disorder the number of painful body sites and self-
reported pain severity is significantly lower after beta-blockade when compared to placebo 
[6]. The clinical implication of these findings is that use of adrenergic receptor antagonists 
might reduce the prevalence and severity of chronic pain.  
Antagonists to α and β-adrenergic receptors have been used for decades, particularly in the 
treatment of hypertension. Because hypertension is extremely common among OA patients 
we hypothesized that joint pain levels will be lower in those whose anti-hypertensive therapy 
includes α or β-blockers than in those whose therapy is based on a different molecular 
pathway, and that this should reduce the requirement for conventional analgesics. We 
investigated this in a case-control study of OA in which participants underwent radiographic 
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assessment of both hips and knees and gave extensive questionnaire information on their 
joint pain, general health, medical diagnoses and use of all prescription drugs including anti-
hypertensive medications [7].  
Subjects and methods: 
Genetics of osteoarthritis and lifestyle (GOAL) study. Hip and knee OA cases were recruited 
from hospital orthopaedic surgery lists in the Nottinghamshire area between 2002 and 2006 
as previously described [7]. Approval for recruitment was obtained from the research ethics 
committees of Nottingham City Hospital and North Nottinghamshire. Standardised pelvis and 
knee radiographs (weight-bearing tibiofemoral and 300 flexion skyline views) were obtained. 
Individuals who had symptomatic and radiographic knee OA defined as Kellgren and 
Lawrence grade ≥2 [8] at either the tibiofemoral or patellofemoral compartment in either 
knee or who had radiographic hip OA (defined as Croft grade ≥3) [9] were included as OA 
cases, regardless of whether or not they had already undergone a total joint replacement 
(TJR) Individuals assessed post TJR were assessed on average 2.2 years post-surgery 
(SD=2.4 years). All included participants had hip or knee pain assessed using the Western 
Ontario and McMaster Universities Arthritis (WOMAC) score. [10] 
Hypertension classification: All participants underwent a clinical examination and detailed 
medical questionnaire. Only participants who reported physician diagnosed hypertension 
and were on at least one prescription antihypertensive medication were included in the 
analyses. 
Other comorbidities: Participants were asked whether they had been diagnosed by a 
physician with comorbidities including asthma, chronic obstructive pulmonary disease, 
anxiety and depression. 
Use of medication: A trained research nurse assessed use of prescription medications by 
participants including anti-hypertensive and analgesic medications. For this, participants 
were asked to show their complete GP prescription or all prescription and OTC medications 
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to the nurse. . Participants also self-reported the duration of use for each medication. The 
names of medications were reviewed by AV and AA to identify the drugs of interest. 
Anti-hypertensive medications were classified as follows: 
− α-adrenergic blocker: doxazosin 
− β-adrenergic blockers: acebutolol, atenolol, bisoprolol, celiprolol co-tenidone, 
metoprolol, nebivolol, propranolol, sotalol, timolol (excluding ocular use for glaucoma) 
− ACE inhibitors: quinapril, enalapril, lisinopril, rampiril, perindopril, trandolapril. 
− Angiotensin II receptor antagonists (ARBs): losartan, irbesartan, olmesartan, 
valsartan, telmisartan. 
− calcium channel blockers (CCBs): amlodipine, felodipine, lercanidipine, nifedipine 
− diuretics: acetazolamide, bendrofluazide, furosemide, indapamide 
 
 Prescription analgesic medications were classified as follows: 
− Opioids: buprenorphine, co-codamol, co-proxamol, codeine, dihydrocodeine, co-
dydramol, solpadol, tramadol. 
− NSAIDs: arthrotec, celecoxib, diclofenac, etodolac, etoricoxib, indomethacin, 
meloxicam, nabumetone, rofecoxib 
− other prescription drugs for pain: amitryptiline, gabapentin, pregabalin  
 
Statistical analysis: The WOMAC pain subscale score is not normally distributed [11]. 
Therefore two approaches were used: (1) we defined joint pain as present using the cut-off 
of WOMAC score that has been used by others for as being moderate joint pain [11], defined 
as a WOMAC score <75 on a 0-100 scale (100=no pain) as the primary outcome in logistic 
regression analyses adjusting for age, sex BMI, history of TJR, joint affected by OA (hip, 
knee or both) and self-reported anxiety and depression. (2) we log transformed the WOMAC 
pain scores and used is as the outcome in linear regressions adjusting for the covariates as 
above. Logistic regression, adjusted for covariates as above was used to examine the 
association between adrenergic receptor blocker prescription and analgesic prescription. All 
statistical analyses were carried out using the R statistical package (https://cran.r-
project.org/) and p<0.05 was set as statistically significant.  
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Results 
The descriptive characteristics of the study participants according to their beta-blocker use 
are presented in Table 1. Overall there were significant differences in the average pain 
scores and in the prevalence of joint pain defined as WOMAC <75. The number and type of 
anti-hypertensive medications taken by the two groups was significantly different as was the 
prevalence of asthma, which reflects prescribing practices for hypertension. [12] 
After adjusting for age, gender, BMI, use of β-blockers was associated with a lower 
prevalence of joint pain (ORjoint_pain = 0.70; 95%CI 0.52-0.93; Figure 1A) This remained 
significantafter further adjustment for knee OA, hip OA, history of TJR, anxiety and 
depression, ( odds ratio adjORjoint_pain= 0.68 ; 95%C.I. 0.51-0.91). A similar result was seen 
with use of adrenergic blockers in general (ORjoint_pain= OR= 0.70; 95%CI 0.52-0.93;) and no 
association was seen with use of α-blockers (Figure 1A). The number of years of being on 
β-blockers was also associated with a reduced risk of joint pain (OR per one year increase in 
duration of use of 0.96 (95%CI 0.93, 0.99; p<0.004). The association between use of β-
blockers and joint pain was similar in indivdiuals with a history of joint replacement but 
ongoing symptomatic OA at un-operated joints (ORjoint_pain= 0.66; 95%C.I. 0.26-0.93) and 
those who had not undergone arthroplasty (ORjoint_pain= 0.75; 95%C.I. 0.44-1.27).  
Prescription of β-blockers was further associated with lower rate of prescription of analgesics 
(ORanalgesics= 0.74; 95% C.I.0.56-0.97). This association was attributable largely to 
prescription of opioids (ORopioids= 0.73; 95%CI 0.54-0.98) (Figure 1B). Importantly, no other 
class of anti-hypertensives showed any association with joint pain (Figure 1C) or with 
prescription of analgesics (Figure 1D).  
Individuals on β-blockers were taking a higher number of antihypertensive medications than 
those not on β-blockers (Table 1). We therefore explored whether this could be a 
confounding factor. However, the number of anti-hypertensive medications did not associate 
with the prevalence of joint pain (ORjoint_pain= 0.92 (95%C.I. 0.70-1.21) and adjusting for this 
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potential confounder did not change the association between β-blockers and prevalent joint 
pain ORjoint_pain= 0.69 (95%CI 0.51-0.94). 
Another significant difference between the two groups was the presence of self-reported 
asthma or chronic obstructive pulmonary disease (COPD). Individuals with asthma or COPD 
in this cohort had a higher prevalence of joint pain (54% in those with self-reported asthma 
or COPD vs 40% in those without). Use of β-blockers is not usually recommended in these 
conditions as it may worsen bronchoconstriction [12], so we assessed whether the 
association between β-blockers and pain could be confounded by asthma/COPD. However, 
after excluding participants with asthma/COPD from the analysis the association between β-
blocker prescription and WOMAC pain remained significant with a similar effect size 
(ORjoint_pain=0.73 (95%C.I. 0.54-0.99);  
Finally to test the robustness of the above approach we used the log transformed WOMAC 
pain scores as the outcome in linear regressions (Table 2). These analyses confirmed that 
beta blocker use is associated with better WOMAC pain scores after adjusting for potential 
confounders, and that the association is essentially the same in men and women and in 
individuals with or without a history of TJR at other joints. No association between WOMAC 
scores and other forms of anti-hypertensive therapy were found (Table 2). 
Discussion 
To our knowledge this is the first study to show that use of β-adrenergic receptor antagonists 
for hypertension in middle-aged and older adults with OA associates with lower levels of joint 
pain and lower use of opioid analgesics. 
Possible confounding was examined in this study. Because β-blockers act by preventing 
release of adrenaline and noradrenaline it is possible that the analgesic benefit could be 
mediated by reducing anxiety which is strongly associated with pain. However, adjusting for 
anxiety and depression did not alter the results. Possible confounding by indication in 
individuals with asthma or COPD was also examined, but after excluding people with these 
Page 8 of 16
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
BRIEF REPORT 
9 
 
diagnoses the associations remained. Therefore, these data support a direct association 
between β-blockers and lower levels of joint pain in this study population. This is consistent 
with recent experiments in murine models of inflammatory and chronic pain showing 
significant anti-nociceptive properties for bupranolol [5] and with the analgesic effect of 
propranolol versus placebo in patients with fibromyalgia or with temporomandibular joint 
disorder [6]. 
There are a number of limitations to this study. Firstly, this is a cross-sectional observation, 
the causality between beta-blockers and joint pain has yet to be established. Secondly, the 
study population was derived from a hospital based case control study for large joint OA, 
many of whom had already undergone arthroplasty at another joint site even though they 
had still ongoing symptomatic OA at other joints, hence selection bias cannot be avoided. 
Thirdly, this is only an observational study, potential confounding factors, especially those 
unknown cannot be fully controlled. More robust method such as randomised controlled trial 
is required to confirm the findings. In addition, the number of years that individuals have 
been on antihypertensive medication was self-reported, we have no data on adherence to 
such medication, for individuals with hypertension and other indications for beta blocker 
prescriptions we cannot be sure that beta-blocker use was for hypertension,. Moreover, this 
study focussed on people with knee or hip OA-related pain as their most significant regional 
pain problem but we did not evaluate which joints were responsible for the pain and we 
cannot determine from our data whether the pain reported in those who had undergone TJR 
is predominantly persistent post-surgical pain or pain from the un-operated OA joints. 
Therefore, further studies are required to address these caveats and to determine the 
generalisability of the data.  
Nevertheless, these results might raise some future research questions for the treatment of 
hypertension in individuals with joint pain. Current guidance from both NICE in the UK and 
the JNC VIII committee in the US state that β-blockers should no longer be preferred as an 
initial therapy for routine hypertension and should be used only when there is a compelling 
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indication other than BP control (e.g. angina or chronic heart failure)[13-14]. If confirmed in 
randomised controlled trials, the data presented here could suggest that in people with 
chronic joint pain β-blockers may be considered as part of their anti-hypertensive regimen. 
More importantly, our results point to an anti-nociceptive value of β-blockers for joint pain 
which deserves further investigation in clinical studies. 
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Table 1. Descriptive characteristics of study participants from a cohort of OA 
trait 
not on beta 
blockers 
beta blocker 
users
(1)
 p-value 
Number of participants 526 347  
Women 46.60% 45.00% 0.62 
Hypertension  100% 100% N/A 
Age years mean (SD) 69.2 (6.8) 69.6 (6.4) 0.79 
BMI kg/m
2
 mean (SD) 30.7 (5.2) 30.9 (5.6) 0.58 
hip OA % 47.80% 53.80% 0.1 
Both knee and hip OA % 41.44% 43.80% 0.49 
knee K/L radiographic grade 
(proportion with grades 2-3-4)
 
(2)
 
0.21/0.56/0.23 00.17/0.65/0.18 0.26 
Croft hip radiographic grade 
(proportion grades 3-4-5) 
(2)
 
0.28/0.52/0.19 0.24/0.60/0.16 0.47 
post TJR
(3)
 65.78% 70.32% 0.161 
Anxiety  13.50% 12.10% 0.54 
Depression 20.70% 18.73% 0.47 
Asthma / COPD 20.72% 5.76% <0.0001 
WOMAC pain score  
(0-100, 100= no pain) 
mean (SD) 
74.6 (24.8) 78.9 (22.7) 0.0106 
Median (range) 
80 (10-100) 
 
85 (15-100) 
 
moderate joint pain 
(WOMAC<75) 
42.20% 34.00% 
0.015 
    
 
number of anti-hypertensive 
drugs taken mean (SD) 
1.41 (0.58) 1.89 (0.80) <0.0001 
α-blocker 9.50% 5.80% 0.069 
β-blockers 0.00% 100.00% N/A 
years on β -blockers mean 
(SD) 
6.9 (6.6) N/A 
ACE inhibitors 37.20% 21.90% <0.0001 
angiotensin II receptor 
antagonist  
7.20% 10.10% 0.13 
calcium channel blockers  31.90% 16.70% <0.0001 
diuretics  55.1%  35.4%  <0.0001 
    
 
opioids  35.40% 28.50% 0.035 
NSAIDs  19.60% 17.60% 0.46 
other prescription drugs for 
pain  
4.60% 3.40% 0.42 
 
(1)
β-blockers included =acebutolol, atenolol, bisoprolol, celiprolol co-tenidone, metoprolol, nebivolol, 
propranolol, sotalol, timolol, excluding ocular 
(2) 
K/L grade only for individuals with a diagnosis of knee 
OA, Croft grade for individuals with a diagnosis of hip OA, refers to unoperated joints. 
(3) 
post TJR= 
post total joint replacement 
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Table 2. Association, expressed as linear regression coefficient (beta) and 95% confidence 
intervals, between use of anti-hypertensive medication and WOMAC pain scores in 
individuals diagnosed with hip or knee OA 
predictor variable adjusted for subset beta 95%CI p-value 
use of β-blockers age sex BMI all 0.033 (0.010-0.056) 0.0058 
use of β-blockers age sex BMI, num. anti 
hypertensive meds, 
history of TJR, anxiety, 
depression, type of 
joints affected (hip, 
knee, both) all 
0.033 (0.009-0.057) 0.0072 
use of β-blockers as above + 
asthma/COPD 
all 0.029 (0.005-0.053) 0.0171 
use of β-blockers 
age BMI male 0.030 (0.001-0.060) 0.0461 
use of β-blockers 
age BMI female 0.033 (-0.004-0.069) 0.0808 
use of β-blockers 
age sex BMI no history of TJR 0.042 (-0.004-0.088) 0.0765 
use of β-blockers 
age sex BMI history of TJR 0.026 (0.001-0.051) 0.0421 
years on β-blockers age sex BMI all 0.003 (0.001-0.005) 0.0071 
use of CCBs age sex BMI all -0.003 (-0.029-0.024) 0.85 
use of ARBs age sex BMI all 0.029 (-0.013-0.071) 0.18 
use of ACE inhibitors age sex BMI all 0.003 (-0.022-0.028) 0.84 
use of diuretics age sex BMI all -0.008 (-0.031-0.016) 0.53 
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Figure 1. (A) Association between use of adrenergic receptor blockers and prevalence of 
joint pain defined as WOMAC pain scores <75 (B) Association between use of β-blockers 
and use of prescription analgesic medication. (C) Association between use of other anti-
hypertensive medication and prevalence of joint pain. (D) Association between use of anti-
hypertensive medication and use of prescription analgesic medication.  
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